Merck & Co., Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2010 to Q1 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Merck & Co., Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q1 2024.
- Merck & Co., Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$51M, a 81.6% increase year-over-year.
- Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.9B, a 21.1% decline from 2022.
- Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.57B, a 939% decline from 2021.
- Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $187M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)